Encyclopedia of contested claims
Early clinical studies suggest psilocybin-assisted therapy may reduce depressive symptoms for some people with treatment-resistant depression, but the evidence base is still developing. Key uncertainties include durability of benefit, optimal dosing and psychotherapy support, safety in broader populations, and how it compares with established treatments.
5 reviewing models concluded the claim is not supported by the available evidence.
The Adjudged panel has not yet completed its review of this claim. This draft summarizes the main issues likely to be considered, including trial design, patient selection, symptom outcomes, adverse events, durability of response, and the difference between regulated clinical psilocybin-assisted therapy and nonmedical use.
Early clinical studies suggest psilocybin-assisted therapy may reduce depressive symptoms for some people with treatment-resistant depression, but the evidence base is still developing. Key uncertainties include durability of benefit, optimal dosing and psychotherapy support, safety in broader populations, and how it compares with established treatments.
The claim asks whether psilocybin is effective for treatment-resistant depression, often abbreviated TRD. In clinical research, this usually refers to depression that has not responded adequately to multiple standard treatments, such as antidepressant medications and psychotherapy.
The strongest version of the claim is not simply that psilocybin can produce a short-term mood change. It is that psilocybin, typically given in a controlled setting with psychological preparation and support, can meaningfully reduce depressive symptoms in people whose depression has been difficult to treat.
This distinction matters because the published trials generally study psilocybin-assisted therapy, not unsupervised psilocybin use. The medical claim depends on structured screening, dosing, monitoring, and follow-up rather than on the compound alone.
Several small to medium-sized studies have reported reductions in depression scores after one or two supervised psilocybin sessions. Some studies include patients with treatment-resistant depression, while others include broader major depressive disorder populations, which limits how directly they apply to TRD.
A notable phase 2 trial in treatment-resistant depression found that a 25 mg dose of synthetic psilocybin was associated with larger symptom reductions than lower-dose comparison groups at an early follow-up point. However, not all participants responded, and some benefits appeared to diminish over time for a portion of patients.
The evidence is promising enough that psilocybin-assisted therapy has attracted regulatory and clinical research interest, including larger trials. At the same time, current studies often involve intensive therapist support, careful exclusion criteria, and specialized settings, which may not reflect ordinary clinical practice.
Safety findings require careful interpretation. Trials report adverse effects such as headache, nausea, anxiety, transient increases in blood pressure, and challenging psychological experiences; people with certain psychiatric histories are often excluded, so population-level safety remains less certain.
A central uncertainty is durability. Some participants show rapid improvement, but researchers are still studying how long benefits last, whether repeat dosing is needed, and what kind of psychological support is essential.
Another uncertainty is comparison with existing treatments for TRD, such as electroconvulsive therapy, transcranial magnetic stimulation, ketamine or esketamine, medication augmentation, and structured psychotherapy. Head-to-head evidence remains limited.
There are also practical and ethical questions about implementation. If approved, psilocybin-assisted treatment would likely require trained clinicians, screening protocols, monitored sessions lasting several hours, and post-session integration, which may affect access, cost, and safety.
The umbrella claim is actually several claims bundled into one. Each needs its own evaluation.
| Model | Part 1 | Part 2 | Part 3 | Overall |
|---|---|---|---|---|
| Grok 4.3 | Yes · 73% | Unclear · 42% | No · 76% | Mixed · 70% |
| Mistral Medium 3.5 | Yes · 73% | Unclear · 42% | No · 76% | No · 70% |
| OpenAI GPT-5.4 | Yes · 73% | Unclear · 42% | No · 76% | No · 65% |
| Llama 4 Maverick | Yes · 73% | Unclear · 42% | No · 76% | No · 70% |
| Gemini 3.1 Pro | Yes · 73% | Unclear · 42% | No · 76% | No · 85% |
| Claude Opus 4.7 | Yes · 73% | Unclear · 42% | No · 76% | Mixed · 68% |
| DeepSeek V4 Pro | Yes · 73% | Unclear · 42% | No · 76% | Mixed · 65% |
| Qwen 3.7 Max | Yes · 73% | Unclear · 42% | No · 76% | No · 70% |
| GLM 5.1 | Yes · 73% | Unclear · 42% | No · 76% | Mixed · 85% |
| Kimi K2.6 | — | — | — | Incomplete |
The current evidence leans one way. But we're not committed to the conclusion, we're committed to the evidence.
Psilocybin-assisted therapy shows short-term reductions in depressive symptoms for some adults with treatment-resistant depression in controlled early-phase trials, but lacks established long-term durability, o...
Psilocybin-assisted therapy shows promise in reducing depressive symptoms in some adults with treatment-resistant depression (TRD) in controlled clinical settings over the short term, but its long-term effectiv...
Mostly supported, with important caveats. Psilocybin-assisted therapy appears capable of reducing depressive symptoms in some adults with treatment-resistant depression in controlled clinical settings over the short term. But the stronger claim that it has established long-term effectiveness, or that it is ready as a routine stand-alone treatment outside specialized supervision, is not supported. Confidence: moderate. What the evidence supports - Short-term benefit: Supported. - Recent randomized clinical trials, i...
Psilocybin-assisted therapy shows promise in reducing depressive symptoms in some adults with treatment-resistant depression, particularly in the short term. Confidence in this assessment is moderate due to the...
Psilocybin-assisted therapy demonstrates promising short-term effectiveness for treatment-resistant depression (TRD) in controlled clinical settings, but it is not yet established as a long-term or routine stan...
Psilocybin-assisted therapy shows promising short-term efficacy for some adults with treatment-resistant depression (TRD), but it is not yet an established standard treatment, and key questions about durability...
The evidence from early-phase clinical trials suggests that psilocybin-assisted therapy can produce rapid and substantial reductions in depressive symptoms for some adults with treatment-resistant depression in...
Psilocybin demonstrates promising short-term efficacy for treatment-resistant depression when administered in highly controlled clinical settings alongside psychological support, but it is not yet an establishe...
Psilocybin-assisted therapy shows short-term efficacy in reducing depressive symptoms for treatment-resistant depression in controlled clinical settings, but it does not have established long-term effectiveness...
